TrialSignal
Clinical trial intelligence report
A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03518320
Status
TERMINATED
Phase
Phase 1
Sponsor
Taris Biomedical LLC
Executive brief
Investment-Ready Snapshot
The clinical trial investigated the safety and tolerability of TAR-200, a drug delivery system, in combination with Nivolumab for patients with muscle-invasive bladder cancer (MIBC) scheduled for radical cystectomy. The study was sponsored by Taris Biomedical LLC in collaboration with Bristol-Myers Squibb.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03518320
Indication
Bladder Cancer TNM Staging Primary Tumor (T) T2
Modality
monoclonal antibody
Target
Muscle-Invasive Bladder Cancer
Intervention
Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.